Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + bendamustine + mitoxantrone followed by rituximab consolidation in elderly untreated advanced follicular lymphoma
2009-012337-29Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, bendamustine and mitoxantrone in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete remission rate. Started Jan 2012; status: completed.
02
Drugs
rituximabbendamustinemitoxantrone
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2009-012337-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012337-29.